Clene Inc. (NASDAQ:CLNN) Given Consensus Rating of “Moderate Buy” by Analysts

Clene Inc. (NASDAQ:CLNN) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $32.60.

Several research analysts recently issued reports on the stock. D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of Clene in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a research note on Tuesday, October 14th. Benchmark reiterated a “buy” rating on shares of Clene in a report on Thursday, December 4th. Finally, UBS Group reiterated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd.

Insider Buying and Selling

In other Clene news, major shareholder Chidozie Ugwumba sold 72,748 shares of Clene stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $6.73, for a total transaction of $489,594.04. Following the transaction, the insider directly owned 521,620 shares of the company’s stock, valued at approximately $3,510,502.60. This trade represents a 12.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 267,744 shares of company stock worth $1,790,299 in the last quarter. 35.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Clene

A number of institutional investors have recently made changes to their positions in CLNN. Scoggin Management LP raised its position in Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after purchasing an additional 107,250 shares during the period. Lunt Capital Management Inc. boosted its position in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after buying an additional 1,250 shares during the period. Jones Financial Companies Lllp bought a new position in shares of Clene during the third quarter valued at about $29,000. Finally, Jane Street Group LLC purchased a new position in shares of Clene in the second quarter worth about $47,000. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene Trading Down 1.7%

CLNN stock opened at $6.25 on Monday. The company’s 50 day moving average is $8.30 and its 200 day moving average is $6.31. The stock has a market cap of $64.56 million, a price-to-earnings ratio of -1.84 and a beta of 0.79. Clene has a 1-year low of $2.28 and a 1-year high of $13.50.

Clene (NASDAQ:CLNN) last announced its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. As a group, sell-side analysts forecast that Clene will post -5.19 EPS for the current fiscal year.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).